Intravesical administration of bacillus Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis, plays an important role in adjuvant treatment of superficial bladder cancer. Severe adverse events due to this treatment are rare. Complications of varying character and severity have been described, including rare BCG-related vascular infections. In this writing, we present a case of mycotic abdominal aneurysm caused by M. bovis infection related to prior intravesical BCG instillation. (J Vasc Surg Cases and Innovative Techniques 2018;4:122-5.) 
Bacillus Calmette-Guérin (BCG) is a weakened strain of Mycobacterium bovis. BCG is used as adjuvant intravesical therapy in non-muscle-invasive bladder cancer.
Adverse events occur in <5% of cases, ranging from mild local symptoms to severe sepsis and death. 1 It can be challenging to link previous intravesical BCG instillation to a patient's symptoms. We describe a case of mycotic aortic aneurysm caused by M. bovis infection after intravesical BCG instillation 2 years earlier. The patient agreed to publication of his case. Three samples of para-aortic tissue were cultured. One sample contained M. bovis. Pathologic evaluation showed extensive granulomatous and necrotizing inflammation of the aorta.
CASE REPORT
However, histologic Ziehl-Neelsen staining used to identify acid-fast organisms such as M. bovis was negative. DNA analyses showed that the cultured strain of M. bovis was identical to the one used for the BCG solution administered in 2013. The conclusion was that this BCG solution was the source The patient was transferred to the general surgery ward. His condition improved, and he was transferred to a rehabilitation center 2 months after surgery. Antimicrobial treatment with rifampicin, ethambutol, and isoniazid had to be continued. Three months after discharge, the patient was again admitted with fever, generalized weakness, and malaise. Physical examination showed no abnormalities apart from fever and tachycardia. Blood tests showed an elevated C-reactive protein level (43 mg/L) and leukocytosis (18.2 Â 10 9 /L). A CT scan showed a fluid collection on the left dorsolateral side of the bovine aorta tube graft extending into the left psoas muscle (Fig 2) . CT-guided drainage was performed, and 60 mL of fluid was sent for culture. Analyses showed mycobacterium in the aspirated fluid.
Initially, it was unclear whether the collection resulted from active M. bovis infection or from paradoxical abscess formation during antituberculosis therapy. 2 The patient's case was discussed with a tertiary tuberculosis center. The team decided to initiate treatment for both active infection and paradoxical abscess formation. The antibiotic treatment regimen was changed to rifampicin, ethambutol, and moxifloxacin. The paradoxical abscess formation was treated with drainage and dexamethasone.
The patient's condition improved substantially, and a follow-up CT scan showed a significant decrease of the collection, so the 
DISCUSSION
BCG is a live attenuated strain of M. bovis and is widely accepted as bladder instillation therapy for non-muscleinvasive bladder cancer. The mechanism of antitumor activity is not completely understood but seems to involve immune system stimulation resulting in release of tumor necrosis factor and apoptosis of tumor cells. The most common adverse effects described are fever, hematuria, granulomatous pneumonitis, and hepatitis and, less often, BCG sepsis.
Although it is a rare complication, increasing cases of aortic aneurysm secondary to M. bovis infection after intravesical BCG therapy have been reported, mainly in the past two decades. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Leo et al reviewed 20 cases and noted that patients often present with unspecified symptoms (weight loss, fatigue, malaise) that are often misinterpreted. They also noted a substantial spread in the time interval from BCG treatment to symptoms, ranging from 14 to 77 months.
The exact pathomechanism remains unclear. Although risk factors for reactivation of mycobacterial disease have been described, no risk factors specific for vascular complication after BCG treatment have been identified so far. 13 No imaging studies had been performed that could rule out a pre-existing aortic aneurysm. It remains unclear whether a pre-existing aneurysm had been infected or a primary infection of a normal aorta had occurred.
CONCLUSIONS
Infection of an aortic aneurysm is a potentially life-threatening complication of BCG therapy. The rarity, late appearance, unspecific clinical signs, and low awareness create challenges in diagnosis of this complication.
In all patients with a history of BCG therapy and unspecified clinical signs, a mycotic aneurysm of the aorta must be ruled out. Furthermore, we advise additional research into the risk factors contributing to this complication. 
